XOMA (XOMA Royalty Corporation Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by XOMA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-16 | BVF II GP LLC | 10%+ Owner | U | — | — |
| 2026-07-14 | Jeffrey Trigilio | Chief Financial Officer | J | — | — |
| 2026-07-14 | Maricel Perea Montano | Chief Legal Officer | J | — | — |
| 2026-07-14 | Owen Hughes | Chief Executive Officer | MIXED | — | — |
| 2026-07-14 | Heather L Franklin | Director | J | — | — |
| 2026-07-14 | Natasha Hernday | Director | MIXED | — | — |
| 2026-07-14 | Bradley Sitko | Chief Investment Officer | MIXED | — | — |
| 2026-07-14 | JOSEPH M LIMBER | Director | MIXED | — | — |
| 2026-07-14 | Barbara Kosacz | Director | J | — | — |
| 2026-07-14 | JACK L WYSZOMIERSKI | Director | J | — | — |
| 2026-07-14 | MATTHEW D PERRY | Director | J | — | — |
| 2020-12-15 | MATTHEW D PERRY | Director | Buy | — | — |
| 2020-12-15 | BVF GP HOLDINGS LLC | 10%+ Owner | Buy | — | — |
| 2020-11-24 | THOMAS M. BURNS | SVP, Finance & CFO | MIXED | — | — |
| 2020-11-24 | James R Neal | CEO | MIXED | — | — |
| 2020-11-06 | THOMAS M. BURNS | SVP, Finance & CFO | MIXED | — | — |
| 2020-11-06 | James R Neal | CEO | MIXED | — | — |
| 2020-09-23 | BIOTECHNOLOGY VALUE FUND L P | 10%+ Owner | Buy | — | — |
| 2020-09-10 | Biotechnology Value Trading Fund OS LP | — | Buy | — | — |
| 2020-09-01 | BIOTECHNOLOGY VALUE FUND II LP | 10%+ Owner | Buy | — | — |
| 2020-08-25 | BVF Partners OS Ltd. | — | Buy | — | — |
| 2020-08-20 | BVF PARTNERS L P/IL | 10%+ Owner | Buy | — | — |
| 2020-08-14 | BVF GP HOLDINGS LLC | 10%+ Owner | Buy | — | — |
| 2020-07-02 | Natasha Hernday | Director | A | — | — |
| 2020-05-27 | JACK L WYSZOMIERSKI | Director | A | — | — |
| 2020-05-27 | MATTHEW D PERRY | Director | A | — | — |
| 2020-05-27 | Barbara Kosacz | Director | A | — | — |
| 2020-05-27 | JOSEPH M LIMBER | Director | A | — | — |
| 2020-05-27 | W DENMAN VAN NESS | Director | A | — | — |
| 2020-04-17 | Biotechnology Value Trading Fund OS LP | — | C | — | — |
| 2020-03-27 | BVF II GP LLC | 10%+ Owner | Buy | — | — |
| 2020-03-24 | James R Neal | CEO | Buy | — | — |
| 2020-03-23 | James R Neal | CEO | Buy | — | — |
| 2020-03-20 | BIOTECHNOLOGY VALUE FUND II LP | 10%+ Owner | Buy | — | — |
| 2020-03-17 | BVF I GP LLC | 10%+ Owner | Buy | — | — |
| 2020-03-16 | THOMAS M. BURNS | SVP, Finance & CFO | A | — | — |
| 2020-03-16 | James R Neal | CEO | A | — | — |
| 2020-01-16 | James R Neal | CEO | X | — | — |
| 2019-12-20 | MARK N LAMPERT | 10%+ Owner | MIXED | — | — |
| 2019-11-08 | James R Neal | CEO | MIXED | — | — |
| 2019-09-20 | James R Neal | Chief Executive Officer | MIXED | — | — |
| 2019-09-20 | THOMAS M. BURNS | Sr. VP, Finance and CFO | MIXED | — | — |
| 2019-05-20 | JACK L WYSZOMIERSKI | Director | A | — | — |
| 2019-05-20 | JOSEPH M LIMBER | Director | A | — | — |
| 2019-05-20 | Barbara Kosacz | Director | A | — | — |
| 2019-05-20 | MATTHEW D PERRY | Director | A | — | — |
| 2019-05-20 | W DENMAN VAN NESS | Director | A | — | — |
| 2019-05-14 | W DENMAN VAN NESS | Director | Sell | — | — |
| 2019-05-14 | Biotechnology Value Trading Fund OS LP | — | Buy | — | — |
| 2019-02-15 | DEEPSHIKHA DATTA | Chief Business Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,194,410 | — |
| — | — | 2,022,816 | — |
| — | 10%+ Owner | 1,948,819 | — |
| — | — | 1,941,035 | — |
| — | 10%+ Owner | 1,335,192 | — |
| — | 10%+ Owner | 1,335,192 | — |
| — | Director | 870,308 | — |
| — | Director | 741,631 | — |
| — | 10%+ Owner | 355,527 | — |
| — | 10%+ Owner | 171,336 | — |
| — | 10%+ Owner | 171,336 | — |
| — | Director | 104,451 | — |
| — | CEO | 38,648 | — |
| — | Director | 23,372 | — |
| — | Sr. VP Clinical Dev. & CMO | 18,211 | — |
| — | SVP, Finance & CFO | 10,238 | — |
| — | Director | 9,944 | — |
| — | Chief Commercial Officer | 9,921 | — |
| — | Exec. VP & CSO | 8,419 | — |
| — | Director | 6,466 | — |
| — | CEO | 5,995 | — |
| — | CFO & VP Finance | 5,723 | — |
| — | Director | 3,877 | — |
| — | Director | 840 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XOMA quote page; the site-wide leaderboard is on the insider transactions hub.